Business
Board Appointment
Board Appointment.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5255C Scancell Holdings Plc 18 June 2019 \n\n18 June 2019\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nBoard Appointment\n \nScancell, the developer of novel immunotherapies for the treatment of cancer, announces that, further to the Company's announcement on 13 June 2019, Martin Diggle, Co-Founder and Portfolio Manager of Vulpes Investment Management, has been appointed to the Company's Board of Directors (the \"Board\") as a Non-Executive Director with immediate effect. \n \nMr Diggle has over 30 years' experience in investment banking and fund management and has been an investor in life sciences and biotechnology companies for nearly 20 years. He is also an expert in Emerging Markets and Russia, where he was previously a partner and director of UBS Brunswick. He holds a Master's Degree in Philosophy, Politics and Economics from University of Oxford. \n \n \nAdditional Information\nIn accordance with the AIM Rules, the following information required to be disclosed in relation to Martin Diggle is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules.\n \nFull name and age\n \nMartin Henry Diggle, 57 years old\n \nCurrent beneficial shareholding in the Company \n \nMartin Diggle is a director and partner in Vulpes Investment Management and manages the Vulpes Life Sciences Fund which is the registered holder of 77,559,311 ordinary shares, representing approximately 16.67 per cent. of Scancell's ordinary share capital. \n \n\n\n\nCurrent Directorships \n\n\nPast Directorships in the previous five years\n\n\n\n\nChronos Therapeutics Limited \n\n\nN/A\n\n\n\n\nOxford BioMedica plc\n\n\n\n\n\n\n\nProteome Sciences plc\n\n\n\n\n\n\n \nFor Further Information: \n \n\n\n\nScanc...